{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:06:33Z","timestamp":1792181193263,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystitis is a bacterial infection of the bladder that occurs in about half of women at least once in their lifetime. Antibiotics such as nitrofurantoin are used to treat cystitis, but antibiotic resistance is a concern, especially for recurrent infections. Here we report an open-label, randomized, single-centre, phase 2 study to analyse the acute and long-term safety and efficacy of the IL-1 receptor antagonist anakinra, compared with nitrofurantoin, in recurrent cystitis. A total of 30 adult female patients with a documented history of recurrent cystitis and a current acute cystitis episode were randomized in a 2:1 ratio to treatment with anakinra (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) or nitrofurantoin (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910) for 5\u2009days. Primary and secondary efficacy end-points were reached, defined as the reduction in typical symptoms, measured by the acute cystitis symptom score (day 5), longitudinal symptom scores, recurrence rates, quality of life, gene expression analysis and microbiology at follow-up on days 15 and 30 and at 6\u2009months. Symptom scores were decreased in the anakinra (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and nitrofurantoin (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) arms after 5\u2009days and remained low after 15\u2009days, 30\u2009days and 6\u2009months. Recurrences were less frequent after 6\u2009months in both treatment groups compared with the 6-month pre-enrolment history (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001 for anakinra and\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004 for nitrofurantoin), and the quality of life was increased, without adverse effects. Immune gene expression was rapidly inhibited in the anakinra-treated patients but not in the nitrofurantoin group. Targeted innate immune inhibition therapy shows non-inferiority to nitrofurantoin in patients with recurrent acute cystitis. German Clinical Trials Register ID:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/drks.de\/search\/en\/trial\/DRKS00025964\" ext-link-type=\"uri\">DRKS00025964<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41564-026-02262-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:03:23Z","timestamp":1770890603000},"page":"638-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-671X","authenticated-orcid":false,"given":"Ines","family":"Ambite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-1841","authenticated-orcid":false,"given":"Adrian","family":"Pilatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Buch-Heberling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-1350","authenticated-orcid":false,"given":"Gabriela","family":"Godaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-0553","authenticated-orcid":false,"given":"Catharina","family":"Svanborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2262_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41585-022-00602-4","volume":"19","author":"D Butler","year":"2022","unstructured":"Butler, D. et al. Immunomodulation therapy offers new molecular strategies to treat UTI. Nat. Rev. Urol. 19, 419\u2013437 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"2262_CR2","doi-asserted-by":"publisher","first-page":"e1005848","DOI":"10.1371\/journal.ppat.1005848","volume":"12","author":"I Ambite","year":"2016","unstructured":"Ambite, I. et al. Molecular basis of acute cystitis reveals susceptibility genes and immunotherapeutic targets. PLoS Pathog. 12, e1005848 (2016).","journal-title":"PLoS Pathog."},{"key":"2262_CR3","doi-asserted-by":"publisher","first-page":"336ra359","DOI":"10.1126\/scitranslmed.aaf1156","volume":"8","author":"M Puthia","year":"2016","unstructured":"Puthia, M. et al. IRF7 inhibition prevents destructive innate immunity\u2013a target for nonantibiotic therapy of bacterial infections. Sci. Transl. Med. 8, 336ra359 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2262_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28634-0","volume":"8","author":"DSC Butler","year":"2018","unstructured":"Butler, D. S. C. et al. Neuroepithelial control of mucosal inflammation in acute cystitis. Sci. Rep. 8, 11015 (2018).","journal-title":"Sci. Rep."},{"key":"2262_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/pathogens13010042","volume":"13","author":"I Ambite","year":"2023","unstructured":"Ambite, I. et al. Therapeutic effects of IL-1RA against acute bacterial infections, including antibiotic-resistant strains. Pathogens 13, 42 (2023).","journal-title":"Pathogens"},{"key":"2262_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88093-2","volume":"15","author":"I Ambite","year":"2025","unstructured":"Ambite, I. et al. Multitarget mechanism of MYC inhibition by the bacterial ion protease in disease. Sci. Rep. 15, 6778 (2025).","journal-title":"Sci. Rep."},{"key":"2262_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000356177","volume":"92","author":"JF Alidjanov","year":"2014","unstructured":"Alidjanov, J. F. et al. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol. Int. 92, 230\u2013236 (2014).","journal-title":"Urol. Int."},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"175628721983217","DOI":"10.1177\/1756287219832172","volume":"11","author":"M Medina","year":"2019","unstructured":"Medina, M. & Castillo-Pino, E. An introduction to the epidemiology and burden of urinary tract infections. Ther. Adv. Urol. 11, 1756287219832172 (2019).","journal-title":"Ther. Adv. Urol."},{"key":"2262_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08207-x","volume":"23","author":"M O\u2019Brien","year":"2023","unstructured":"O\u2019Brien, M. et al. Unmet needs in uncomplicated urinary tract infection in the United States and Germany: a physician survey. BMC Infect. Dis. 23, 281 (2023).","journal-title":"BMC Infect. Dis."},{"key":"2262_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","volume":"17","author":"FME Wagenlehner","year":"2020","unstructured":"Wagenlehner, F. M. E. et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat. Rev. Urol. 17, 586\u2013600 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"2262_CR11","doi-asserted-by":"crossref","unstructured":"The Lancet. Antimicrobial resistance. The Lancet 403, 2349 (2024).","DOI":"10.1016\/S0140-6736(24)01076-6"},{"key":"2262_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38919-8","volume":"13","author":"KG Naber","year":"2023","unstructured":"Naber, K. G. et al. Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. Sci. Rep. 13, 12077 (2023).","journal-title":"Sci. Rep."},{"key":"2262_CR13","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.cmi.2022.06.017","volume":"28","author":"Y Kaussner","year":"2022","unstructured":"Kaussner, Y. et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin. Microbiol. Infect. 28, 1558\u20131566 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"2262_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000448591","volume":"97","author":"JF Alidjanov","year":"2016","unstructured":"Alidjanov, J. F. et al. The acute cystitis symptom score for patient-reported outcome assessment. Urol. Int. 97, 402\u2013409 (2016).","journal-title":"Urol. Int."},{"key":"2262_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4111\/icu.20200060","volume":"61","author":"JF Alidjanov","year":"2020","unstructured":"Alidjanov, J. F. et al. Acute cystitis symptom score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy. Investig. Clin. Urol. 61, 498\u2013507 (2020).","journal-title":"Investig. Clin. Urol."},{"key":"2262_CR16","doi-asserted-by":"publisher","first-page":"h6544","DOI":"10.1136\/bmj.h6544","volume":"351","author":"I Gagyor","year":"2015","unstructured":"Gagyor, I. et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. Br. Med. J. 351, h6544 (2015).","journal-title":"Br. Med. J."},{"key":"2262_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.cmi.2021.05.032","volume":"27","author":"I Gagyor","year":"2021","unstructured":"Gagyor, I. et al. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin. Microbiol. Infect. 27, 1441\u20131447 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"2262_CR18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1302186","volume":"369","author":"TM Hooton","year":"2013","unstructured":"Hooton, T. M., Roberts, P. L., Cox, M. E. & Stapleton, A. E. Voided midstream urine culture and acute cystitis in premenopausal women. N. Engl. J. Med. 369, 1883\u20131891 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2262_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota, J. et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin. Rheumatol. 37, 2233\u20132240 (2018).","journal-title":"Clin. Rheumatol."},{"key":"2262_CR20","first-page":"CD008794","volume":"2011","author":"JA Singh","year":"2011","unstructured":"Singh, J. A. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011, CD008794 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2262_CR21","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon, K. et al. The PRECIS-2 tool: designing trials that are fit for purpose. Br. Med. J. 350, h2147 (2015).","journal-title":"Br. Med. J."},{"key":"2262_CR22","first-page":"Doc01","volume":"12","author":"KG Naber","year":"2024","unstructured":"Naber, K. G. et al. Therapeutic strategies for uncomplicated cystitis in women. GMS Infect. Dis. 12, Doc01 (2024).","journal-title":"GMS Infect. Dis."},{"key":"2262_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/jcm10051097","volume":"10","author":"JJ Yoo","year":"2021","unstructured":"Yoo, J. J. et al. Urinary microbiome characteristics in female patients with acute uncomplicated cystitis and recurrent cystitis. J. Clin. Med. 10, 1097 (2021).","journal-title":"J. Clin. Med."},{"key":"2262_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/antibiotics7010006","volume":"7","author":"JF Alidjanov","year":"2018","unstructured":"Alidjanov, J. F., Naber, K. G., Abdufattaev, U. A., Pilatz, A. & Wagenlehner, F. M. E. Reevaluation of the acute cystitis symptom score, a self-reporting questionnaire. Part I. Development, diagnosis and differential diagnosis. Antibiotics 7, 6 (2018).","journal-title":"Antibiotics"},{"key":"2262_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antibiotics7020043","volume":"7","author":"JF Alidjanov","year":"2018","unstructured":"Alidjanov, J. F., Naber, K. G., Abdufattaev, U. A., Pilatz, A. & Wagenlehner, F. M. Reevaluation of the acute cystitis symptom score, a self-reporting questionnaire. Part II. Patient-reported outcome assessment. Antibiotics 7, 43 (2018).","journal-title":"Antibiotics"},{"key":"2262_CR26","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s11136-023-03358-5","volume":"32","author":"K Piontek","year":"2023","unstructured":"Piontek, K. et al. Patient-reported outcome measures for uncomplicated urinary tract infections in women: a systematic review. Qual. Life Res. 32, 2137\u20132153 (2023).","journal-title":"Qual. Life Res."},{"key":"2262_CR27","doi-asserted-by":"publisher","unstructured":"Ambite, I. Targeted innate immune inhibition therapy for treatment of recurrent acute cystitis. Code Ocean https:\/\/doi.org\/10.24433\/CO.8500789.v1 (2025).","DOI":"10.24433\/CO.8500789.v1"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02262-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:57:29Z","timestamp":1772708249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02262-1","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.A., S.A., G.G. and C.S. are part-time employees of Hamlet BioPharma and Lund University. I.A. and C.S. are shareholders in Hamlet BioPharma. Patents protecting the use of the IL-1RA for the treatment of cystitis have been granted (EP3242680, with C.S. and I.A. as inventors). F.W. is a speaker of the DFG (German Research Foundation)-funded research group BARICADE (FOR5427\/1-466687329) and a member of the DZIF (German Center for Infection Research; site: Giessen-Marburg-Langen). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}